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Relationship between estrogen, progesterone and epithelial growth factor
receptor status of primary breast cancer and the survival of women patients
S∏awomir Mazur, El˝bieta Skasko, Zygmunt Paszko
A i m.  The aim of the study was to evaluate the influence of estrogen (ER), progesterone (PR), and epidermal growth factor
(EGFR) receptor concentration in primary breast cancer tissues on the survival of patients. Methods: The receptors were
determined by biochemical radiocompetitive methods. Disease free survival of women patients (DFS) and overall survival (OS)
were determined by the Kaplan – Meier method. 
R e s u l t s.  It has been found that between DFS and ER or PR concentration in primary breast cancer tissue there is
a significant positive relation. There also exists a statistically significant positive relation between the OS of women breast cancer
patients and PR concentration in their cancer tissue. On the other hand, ER concentrations have no impact on OS of the same
group of patients. 
There is no relation between EGFR concentration in breast cancer tissue and both DFS and OS of patients. However, such
a relation may be observed when EGFR concentration is analysed in view of the presence or absence of ER or PR within the
cancer tissue. The presence of higher concentrations of EGFR in breast cancer tissue with a concomitant lack of ER or PR
relates to shorter DFS and OS of patients; while the concomitant lack of both EGFR and ER or PR relates to longer DFS and
OS. Patients presenting with higher concentrations of EGFR and ER or EGFR and PR in their breast cancer tissue achieve
longer DFS and OS, as compared to women presenting with high EGFR concentrations and negligible concentrations of either
ER or PR. 
C o n c l u s i o n s.  To summarise – we believe that the influence of EGFR status in breast cancer tissue on the survival of
women patients depends upon the ER and PR status of the tumour. In the presence of high concentrations of ER or PR in
breast cancer tissue a high concentration of EGFR has a positive impact on DFS and OS of patients, while with the
concomitant lack of PR and ER high EGFR concentrations affect both DFS and OS of patients negatively.  
Zale˝noÊci mi´dzy zawartoÊcià receptorów estrogenów, progesteronu 
i naskórkowego czynnika wzrostu w tkankach pierwotnego raka piersi a prze˝yciem chorych kobiet
C e l  p r a c y.  Celem badaƒ by∏o okreÊlenie zale˝noÊci, jakie zachodzà mi´dzy prze˝yciem kobiet chorych na raka piersi
a zawartymi w ich pierwotnych nowotworach receptorami estrogenów (ER), progesteronu (PR) i naskórkowego czynnika
wzrostu (EGF-R). 
M a t e r i a ∏  i  m e t o d y.  Badania prowadzono u 188 chorych kobiet przez oko∏o 5 lat. SpoÊród obserwacji klinicznych, do
porównaƒ wy∏oniono dwa parametry: a) bezobjawowy pooperacyjny okres prze˝ycia chorych (DFS) oraz  b) ca∏kowite
prze˝ycie chorych (OS). Krzywe prze˝ycia chorych wyliczano wg Kaplana i Meiera, a ich porównania wykonano kilkoma
rangowymi testami statystycznymi: (Log rank test, test Breslowa i test  Tarone - Ware). Receptory ER, PR i EGFR oznaczono
biochemicznymi metodami radiokompetycyjnymi.
W y n i k.  Wykazano, ˝e d∏u˝szym okresom DFS chorych odpowiadajà wi´ksze a krótszym mniejsze st´˝enia ER lub PR
w nowotworze. D∏ugoÊç ca∏kowitego prze˝ycia (OS) kobiet chorych na raka piersi jest powiàzana przede wszystkim ze
st´˝eniem PR w pierwotnym nowotworze. Mi´dzy d∏ugoÊcià OS a st´˝eniami ER w pierwotnym nowotworze wyraênej
zale˝noÊci nie stwierdza si´. St´˝enia EGFR  w tkankach raków piersi ca∏ej puli zbadanych kobiet nie wykazywa∏y znamiennej
wspó∏zale˝noÊci z d∏ugoÊcià DFS lub OS. Jednak˝e zale˝noÊç takà wykazano, gdy st´˝enie EGF-R w nowotworze rozpatrywano
∏àcznie z towarzyszàcymi mu receptorami estrogenów lub progesteronu.
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Introduction
Between the years 1972 and 1998 at the Maria
Sklodowska-Curie Memorial Cancer Centre and Institute
of Oncology we had conducted extensive studies on the
presence of estrogen (ER), progesterone (PR), epithelial
growth factor (EGFR) and insulin-like growth factor
(IGFR) receptors in the tissues of primary breast cancers
in women. We have also correlated the receptor status
of breast cancers with their morphology [1, 2]. These
studies essentially set up our understanding of the
quantitative and qualitative receptor status of primary
breast cancers and allowed us to identify patients most
likely to profit from hormonotherapy. We reported our
results in a number of papers and communications [1-4].
All the receptors listed above may be found in breast
cancer tissue, however their quantitative ratios may vary
between tumours. Some tumours lose the expression of
one of the receptors, while the expression of other
receptors may be preserved or even increased. This
mechanism lies behind the lack of, or presence, of
hormonoreactivity of cancer cells. The relations between
the receptors may significantly influence the processes
of cancer cell division and differentiation. It is a common
belief that these two processes define the biology of the
tumour, thus bearing on the course of the disease and
on patient survival.
The ER and EGFR receptors arouse more interest,
as they are considered to be predictive in the treatment of
breast cancer. ER is believed to be a predictive factor
for hormonotherapy, and EGFR for specialist treatment
based on anti-EGFR antibodies [5, 6], while little
attention is paid to PR and IGFR.
As a predictive and prognostic factor EGFR has been
widely described in literature, however the reports tend to
be contradictory. Some authors present EGFR as
a significantly negative prognostic factor [7-10], others
believe that the prognostic impact of EGFR may be
related to other factors, while a group of authors rule
out the prognostic value of EGFR [11-13].
Our initial reports [14, 15], and data yet unpublished,
suggest that EGFR has no prognostic value for disease
free survival (DFS) and overall survival (OS) of women
with breast cancer when analysed as an independent
parameter. Only in specially selected patient groups –
for instance ER+PR+ or ER–PR–, EGFR appears to
be a predictive factor of patient survival – in the first case
a positive and in the second case a negative factor. [14,
15]. We have also stressed the fact that the presence of
PR in breast cancer tissue is an important, constant and
underestimated prognostic factor [9].
Being in the possession of data on the receptor status
of primary breast cancers in women we have launched
a study aimed at assessing whether the receptor status
of the primary breast cancer lesion may allow for
predicting the course of the disease. Follow-up was
designed to be 5 years. The results were analysed in view
of a couple of different methods of evaluating the
receptor status and several approaches to calculating
survival. This paper presents an analysis of the impact of
ER, PR and EGFR concentration in primary breast
cancer tissue on postoperative disease-free survival (DFS)
and overall survival (OS) performed with the Kaplan-
-Meier method (K-M).
Material and methods
Pa t i e n t  c h a r a c t e r i s t i c s
The study included 184 (83 premenopausal and 101 postmeno-
pausal) women with breast cancer aged between 27 and 83 years
(mean age – 54.5±12.8 SD), treated at the Maria Sklodowska-
-Curie Memorial Cancer Centre and Institute of Oncology in
Warsaw.
All patients were treated surgically; adjuvant hormontherapy
or chemotherapy was applied to 88 patients, while the remaining
96 patients received no adjuvant therapy.
Follow-up of patients was set at a minimum of 5 years. In the
material there were 134 cases of ductal carcinoma, 30 cases of
lobular carcinoma and 20 cases of other carcinomas. The
morphological studies included determination of the histological
type of the tumours according to the present WHO classification
[16].
Determination of estrogens and progesterone receptors in the
cytosol fraction.
The receptors of estrogens and progesterone were
determined in the cytosol fraction by the radiocompetitive
charcoal-dextran method of multipoint assay or in one point
assay analysis at maximal saturating concentrations of labelled
hormones. The results of receptor determinations were
expressed in fmoles/mg of cytosol protein (fm/mg c.p.). The
details of determination have been described elsewhere [1]. The
concentration of protein in the cytosol and membrane fractions
was determined with the Lowry method [17].
Determination of epidermal growth factor receptors.
For EGF receptor determination the radiocompetitive
method was applied. EGF receptor was determined in mem-
brane fraction using one-point assay analysis at maximal
saturating concentration (4nM 125I-EGF) with the use of
triplicate samples for total and unspecific bindings. In some
cases the multipoint assay of EGFR was used. The details of
determination have been described elsewhere [2,3]. The results
of receptor determinations were expressed in fmols/mg of
membrane protein (fm/mg m.p.).
S t a t i s t i c  m e t h o d s
DFS and OS analysis was performed with the Kaplan-Meier
method; (SPSS software).
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W n i o s k i.  ObecnoÊç w rakach piersi du˝ych st´˝eƒ EGF-R przy jednoczesnym braku lub znikomych st´˝eniach ER lub PR
wià˝e si´ z krótszym okresem DFS i OS kobiet, natomiast du˝e st´˝enia  EGF-R w rakach piersi w obecnoÊci du˝ych st´˝eƒ
ER i  PR powiàzane by∏y z d∏u˝szymi prze˝yciami chorych. 
Key words: estrogen receptors, epidermal growth factor receptors, progesterone receptors, patient survival
S∏owa kluczowe: receptory estrogenów, progesteronu i naskórkowego czynnika wzrostu, prze˝ycia chorych
Results
1. Relations between ER concentration in breast cancer
tissue of women patients and their DFS or OS.
Results are presented in Table 1 (some also illustrated
on figures). Data shows that in women with lesser ranges
of ER concentrations (0-9; 0-20; 0-30; 0-40; 0-60 and 0-90
fm/mg c.p., Table I, pos. 1a-6a) arithmetic mean values of
DFS were between 47-49 months. In women with greater
ranges of ER concentrations (10-400; 21-400; 31-400;
41-400; 61-400 and 91-400 fm/mg c.p.; Table I; pos. 1b-6b)
mean DFS values were between 50-64 months. Generally,
the higher the ER concentration – the longer DFS.
However, differences between mean DFS at ER con-
centrations of 0-9 fm/mg and 10-400 fm/mg c.p. and,
respectively, 0-20 fm/mg c.p. and 21-400 fm/mg c.p. fail to
reach statistical significance (see Table I; groups 1 and
2). The lowest ER concentrations above which the length
of DFS increases significantly lies between 30 fm/mg c.p.
and 40 fm/mg c.p. (for example Figure 1a).
The relations between OS and ER concentrations
in primary breast tumours are also presented in Table
I (OS). We have compared the OS of women with higher
and lower ER concentrations. The ranges of higher and
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Table I. The relationships between DFS and OS of patients with breast cancer and the concentration of estrogen receptors in their tumours
N0 of Ranges of compared DFS – months OS – months
group ER concentrations Mean survival ± SE Significance level Mean survival ± SE Significance level 
(fm/mg c.p.) Confidence limit* three methods Confidence limit* three methods 
of calculation** of calculation**
(Number of cases ) Difference between Difference between
in group groups groups
a 0 – 9 (53) 48 ± 3 (42–54) 0.5566 55 ± 2 (52–59) 0.6910
1. vs 2 0.5871 7 0.5635
b 10 – 400 (135) 50 ± 2 (47–54) 0.5841 62 ± 2 (59–66) 0.6061
a 0 – 20 (99) 49 ± 2 (44–53) 0.4233 55 ± 2 (51–59) 0.2328
2. vs 1 0.4796 9 0.2029
b 21 – 400 (89) 50 ± 3 (46–55) 0.4603 64 ± 2 (60–69) 0.2241
a 0 – 30 (127) 48 ± 2 (44–52) 0.0476 60 ± 2 (56–64) 0.2007
3. vs 6 0.0587 1 0.1344
b 31 – 400 (61) 54 ± 3 (49–59) 0.0534 59 ± 2 (55–62) 0.1643
a 0 – 40 (140) 48 ± 2 (44–51) 0.0250 61 ± 2 (57–64) 0.1087
4. vs 7 0.0226 2 0.0923
b 41 – 400 (48) 55 ± 3 (50–61) 0.0223 59 ± 2 (56–63) 0.0992
a 0 – 60 (140) 47 ± 2 (43–51) 0.0242 61 ± 2 (58–65) 0.2808
5. vs 9 0.0140 1 0.1751
b 61 – 400 (48) 56 ± 2 (52–61) 0.0182 60 ± 2 (56–65) 0.2182
a 0 – 90 (173) 48 ± 2 (45–52) 0.0168 61 ± 2 (58–65) 0.0674
6. vs 16 0.0120 3 0.0719
b 91 – 400 (15) 64 ± 1 (52–61) 0.0132 64 ± 1 (62–66) 0.0803
* Confidence limits set at 95%
** Parameters of DFS and OS calculated by the Kaplan – Meier method; significance level between groups “a” and “b” calculated by the Log rank
test, the Breslow test and the Tarone – Ware test; results expressed as three consecutive values
Figure 1a
Figures 1a and 1b. The survival curves of women with breast cancer with either higher or lower concentrations of estrogen receptors (ER) within
tumour tissue. The DFS curves (1a) differ significantly, the differences for OS are non-significant (2b)
The significance levels on the figures present only Log Rank test. For complete of significance levels tests see Tables 1 – 4.
Figure 1b
lower concentrations were the same to those analysed
for DFS. The mean OS values of women with a lower
ranges of ER concentration were 55-61 months, and with
a higher ranges of ER – 59-64 months. The differences in
survival between the groups with higher and lower ER
concentrations only in two cases reached as much as 7
and 9 months (Table I; OS pos. 1 and 2), while in the
remaining cases they varied between 1 and 3 months,
however all differences failed to reach statistical
significance, e.g. Figure 1b.
2. Relations between PR concentration in breast cancer
tissue of women patients and their DFS or OS.
We performed comparisons between groups with lower
ranges of PR concentrations (0-4; 0-9; 0-20; 0-30; 0-40;
0-60 and 0-90 fm/mg c.p., Table II; pos. 1a-7a) and higher
ranges of PR concentration (5-1200; 10-1200; 21-1200;
31-1200; 41-1200; 61-1200; and 91-1200 fm/mg c.p.,
Table II, pos. 1b-7b). Results are presented in Table II,
and some are shown on figures.
Data shows that in women with a lesser PR
concentration mean values of DFS were shorter (41-47
months). In women with greater PR concentrations mean
values of DFS were longer (53-58 months). In all groups
of patients compared relating to the lower or higher PR
concentration these differences were statistically
significant, e.g. Figure 2a.
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Table II. The relationships between DFS and OS of patients with breast cancer and the concentration of progesterone receptor in their tumours
N0 of Ranges of compared DFS – months OS – months
group PR concentrations Mean survival ± SE Significance level Mean survival ± SE Significance level 
(fm/mg c.p.) Confidence limits* three methods Confidence limits* three methods 
of calculation** of calculation**
(Number of cases ) Difference between Difference between
groups groups
a 0 – 4 (51) 41 ± 3 (34–48) 0.0320 49 ± 3 (43–55) 0.0017
1 vs 12 0.0190 16 0.0020
b 5 –1200 (137) 53 ± 2 (49–56) 0.0240 65 ± 2 (62–68) 0.0019
a 0 – 9 (72) 44 ± 3 (38–49) 0.0105 52 ± 2 (48–57) 0.0257
2 vs 9 0.0084 13 0.0311
b 10 – 1200 (116) 53 ± 3 (50–57) 0.0100 65 ± 2 (61–68) 0.0281
a 0 – 20 (97) 45 ± 3 (40–50) 0.0069 53 ± 2 (49–57) 0.0169
3 vs 9 0.0031 13 0.0133
b 21 – 1200 (91) 54 ± 2 (51–58) 0.0047 66 ± 2 (62–70) 0.0141
a 0 – 30 (110) 46 ± 2 (42–51) 0.0320 55 ± 2 (51–58) 0.1130
4 vs 8 0.0125 10 0.0724
b 31 – 1200 (78) 54 ± 2 (50–58) 0.0202 65 ± 2 (61–69) 0.0853
a 0 – 40 (121) 46 ± 2 (42–51) 0.0136 54 ± 2 (51–58) 0.0179
5 vs 9 0.0064 13 0.0159
b 41 – 1200 (67) 55 ± 2 (51–60) 0.0093 67 ± 2 (63–71) 0.0156
a 0 – 60 (140) 47 ± 2 (43–51) 0.0242 55 ± 2 (52–58) 0.0500
6 vs 9 0.0140 12 0.0491
b 61 – 1200 (48) 56 ± 2 (52–61) 0.0182 67 ± 3 (62–72) 0.0460
a 0– 90 (147) 47 ± 2 (44–51) 0.0134 55 ± 2 (57–58) 0.0375
7 vs 11 0.0075 13 0.0323
b 91 – 1200 (41) 58 ± 2 (53–62) 0.0098 68 ± 3 (62–73) 0.0317
* Confidence limits set at 95%
** Parameters of DFS and OS calculated by the Kaplan – Meier method; significance level between groups” a” and “b” calculated by
the Log rank test, the Breslow test and the Tarone – Ware test; results expressed as three consecutive values
Figure 2b
Figures 2a and 2b. The survival curves of women with breast cancer
with either higher or lower concentrations of progesterone receptors
(PR) within tumour tissue. The differences are statistically significant
both for DFS (2a) and OS (2b)
Figure 2a
Relations between OS and PR concentrations in
primary breast tumours are also presented in Table II
(OS). We have compared the OS of women with higher
and lower PR concentrations. The arithmetic means of
OS of women with lower ranges of PR concentrations
were 49-55 months, and with higher ranges – 65-68
months. The differences in survival between the groups
with higher and lower PR were between, 10-16 months.
The differences reached statistical significance in all the
compared groups (e.g. Figure 2b), except for one – the
PR 0-30 and 31-1200 fm/mg c.p. which achieved
probability levels of 0.1130; 0.0724 and 0.0853 (i.e. only
approached the generally accepted significance level 0.05;-
Table II; OS group 4).
3. Relations between EGFR concentration in breast
cancer tissue of women patients and their DFS or OS.
In order to assess the relations between EGFR and DFS
or OS we compared a number of groups of patients who
presented with EGFR concentrations of 0-5; 6-15 and
16-100 fm/mg m.p. Results are presented as survival
curves on figures 3a and 3b. A similar analysis of DFS
and OS was performed for EGFR concentrations from
0-9 fm/mg m.p. and 10-100 fm/mg m.p. (these last results
are not shown in the present paper, for details refer to the
dissertation of S. Mazur MD, Ph.D.) [18].
DFS and OS were analysed with the Kaplan-Meier
method, while significance levels were assessed in three
tests (Log-rank, Breslow and Tarone-Ware). We have
shown that the survival curves calculated according to
EGFR concentrations did not differ. Significance levels
performed for all possible comparisons were in the
0.42-0.88 range for DFS and in the 0.61-0.86 range
for OS.
4. Relations between the concomitant presence or
absence of ER and EGFR or PR and EGFR in breast
cancer tissue of women patients and their DFS or OS.
In the studies cited above we have shown that there exists
a significant correlation between the ER or PR con-
centration in breast cancer tissue and DFS and between
PR concentration and OS. However we had found no
such correlation between EGFR concentration and either
DFS and OS. This appears inconceivable in view of the
fact that in our material there exists a statically significant
negative correlation between EGFR and ER concen-
trations and EGFR and PR concentrations. For EGFR
and ERα=–0.2051; significance level 0.0000; for EGFR
and PRα=–0.1279, significance level 0.014.
In our breast cancer specimens the EGFR
concentrations varied greatly – from zero or indiscernible
values to 9 fm/mg m.p. and from 10-100 fm/mg m.p.. The
former range of concentrations is usually referred to as
EGFR-negative and the latter as EGFR-positive.
In order to investigate the lack of significant relation
between EGFR concentration and DFS or OS we had
performed several analyses. We divided the patients into
two groups – EGFR-negative and EGFR-positive. Then
we analysed the relation between ER or PR concen-
trations and DFS or OS within these groups.
4a. Relations between the ER concentration in EGFR-
negative and EGFR-positive patients and their DFS
or OS.
The results of the analyses are presented in Table III.
and some of them are illustrated on figures. We found
that in EGFR-positive patients with a lack of or very low
ER concentration (Table III, DFS; group 1-3) survival
was shorter than in EGFR-negative patients with a lack of
or very low ER concentration. (mean values of DFS by
10-22 months and mean values of OS by 10-11 months).
These differences were statistically significant (Figure
4a and 4b) or on the verge of significance. With the
increase of ER concentrations (Table III; group 4: ER
range 0-15) these differences decrease to 8 and 5 months,
and become non-significant.
The next series of analyses were performed on
EGFR-negative and EGFR-positive patients with lower
ranges of ER concentrations (0-9; 0-20; 0-30; 0-40; and
0-60 fm/mg c.p., groups 5a-9a) and relatively higher
ranges of ER concentrations (10-400; 21-400; 31-400;
41-400; and 61-400 fm/mg c.p., group 5b-9b). In EGFR-
negative patients with low ER concentration (see Table
III: DFS groups 5–9) the mean DFS values remained
between 49 and 56 months, while in patients with
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Figure 3b
Figures 3a and 3b. The survival curves of women with breast cancer
with three different, increasing ranges of concentrations of EGFR.
The differences between the curves are non-significant both for DFS
(3a) and OS (3b)
Figure 3a
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Table III. The relationships between DFS and OS of patients with breast cancer 
and the concentrations of ER in EGFR-positive or EGFR-negative tumours
N0 EGFR* Ranges of compared DFS – months OS – months
of ER concentrations Mean ± SE Significance  Mean ± SE Significance
group (fm/mg c.p.) (Confidence limit)# level** (Confidence limit)# level** 
(Number of cases ) Difference between Difference between
groups groups
– 0 – 4 (8) 60 ± 4 (52–68) 0.0479
1 vs 22 0.0491 – –
+ 0 – 4 (33) 38 ± 5 (28–48) 0.0480
– 0 – 9 (20) 56 ± 4 (48–63) 0.0812 62  ± 2 (57–66) 0.0406
2 vs 13 0.0480 11 0.0388
+ 0 – 9 (33) 43 ± 4 (45–51) 0.0574 51 ± 3 (44–58) 0.0395
– 0 – 10 (23) 55 ± 3 (49–62) 0.0971 62  ± 2 (58–66) 0.0399
3 vs 10 0.0477 10 0.0392
+ 0 – 10 (37) 45 ± 4 (37–52) 0.0600 52 ± 3 (46–58) 0.0395
– 0 – 15 (42) 53 ± 3 (46–59) 0.3828 58 ± 3 (53–63) 0.4393
4 vs 8 0.2427 5 0.2653
+ 0 – 15 (42) 45 ± 4 (37–52) 0.2879 53 ± 3 (48–59) 0.3096
a) 0 – 9 (20) 56 ± 4 (48–63) 0.2977
– vs 6 0.1967
b) 10 – 400 (99) 50 ± 2 (45–54) 0.2247
5 – –
a) 0 – 9 (33) 43 ± 4 (35–51) 0.1364
+ vs 9 0.1032
b) 10 – 400 (36) 52  ± 3 (46–58) 0.1162
a) 0 – 20 (53) 55 ± 3 (49–60) 0.3668
– vs 2 0.3784
b) 21 – 400 (66) 57 ± 2 (54–61) 0.3933
6 – –
a) 0 – 20 (46) 54 ± 3 (49–60) 0.4662
+ vs 11 0.3874
b) 21 – 400 (23) 65 ± 4 (57–73) 0.4213
a) 0 – 30 (70) 49 ± 3 (43–54) 0.2878 55 ± 2 (50–60) 0.3835
– vs 4 0.3036 3 0.3189
b) 31 – 400 (49) 53 ± 3 (47–58) 0.3008 58 ± 2 (54–62) 0.3599
7
a) 0 – 30 (57) 46 ± 3 (40–51) 0.0824 58 ± 2 (55–67) 0.3440
+ vs 11 0.1019 3 0.2581
b) 31 – 400 (12) 57 ± 5 (47–66) 0.0914 61 ± 3 (55–66) 0.2919
a) 0 – 40 (81) 49 ± 3 (44–54) 0.2317 55 ± 2 (51–60) 0.3246
– vs 5 0.2179 3 0.3492
b) 41 – 400 (38) 54 ± 3 (48–60) 0.2259 58 ± 2 (53–63) 0.3459
8
a) 0 – 40 (59) 45 ± 3 (39–51) 0.0453 61 ± 3 (55–66) 0.1744
+ vs 15 0.0502 2 0.1174
b) 41 – 400 (10) 60 ± 3 (54–67) 0.0472 63 ± 1 (61–65) 0.1383
a) 0 – 60 (98) 56 ± 2 (52–60) 0.5146
– vs 3 0.4294
b) 61 – 400 (21) 59 ± 3 (53–65) 0.4761
9 – –
a) 0 – 60 (62) 61 ± 3 (56–67) 0.3639
+ vs 2 0.2449
b) 61 – 400 (7) 63 ± 1 (61–65) 0.2908
# Confidence limits set at 95%; *EGFR- 0 – 9 fm/mg m.p. *EGFR + ≥10 fm/mg m.p.
** Parameters of DFS and OS were calculated by the Kaplan – Meier method; significance level between groups “a” and “b” calculated by the Log
rank test, the Breslow test and the Tarone – Ware test; results expressed as three consecutive values
relatively higher ER concentrations they varied between
50 and 54 months. The differences in the length of
survival were 6, 4 and 5 months and failed to reach
statistical significance.
In EGFR-positive patients with lower ER
concentration the mean DFS values differed from those
achieved by patients with higher ER concentrations. The
differences increased with the increase in ER concen-
tration (9, 11 and 15 months), while their probability
level progressed from non-significance towards the
point of significance i.e. 0.05 (see: Table III: groups 5, 7
and 8).
Similar analyses were performed for OS (See: Table
III; column OS). In EGFR-negative patients with low
ER concentration the mean OS values remained between
55 and 56 months, while in patients with relatively higher
ER concentrations they varied between 57 and 59 months.
The differences in the length of survival were 2-3 months
and failed to reach statistical significance.
In EGFR-positive patients with lower ER concen-
trations the mean OS values differed from those achieved
by patients with higher ER concentrations. In patients
with low ranges of ER concentrations (see Table III, OS,
groups 6b-9b) the mean OS values remained between 54
and 61 months, while in patients with relatively higher
ranges of ER concentration they varied between 61 and
65 months. The difference in the length of survival was
the greatest in group 6 and reached 11 months, but all the
differences between the groups failed to reach statistical
significance.
4b. Relations between the PR concentration in
EGFR-negative and EGFR-positive patients and their
DFS or OS.
The results are presented in Table IV and some of them
are illustrated on figures. In EGFR-negative (0-9 fm/mg
m.p.) patients who also presented as PR–negative (0-4
fm/mg c.p.) DFS was longer by 16 months than in EGFR-
positive but PR–negative patients. This difference
achieved statistical significance (Table IV: DFS group 1;
Fig. 4c). This difference rapidly fell to 9 months with
a minimal increase of the PR concentration range (0-9
fm/mg c.p.; Table IV: DFS group 2:) and immediately
failed to reach statistical significance.
In another series of analyses we compared the
survival of EGFR negative and EGFR positive patients
correlating with lower or higher ranges of PR con-
centration. Lower ranges of PR concentrations remained
within the 0-4; 0-9; 0-20; 0-30 and 0-40 fm/mg c.p. (groups
3a-8a) and higher ranges of PR concentrations within
the 5-1200; 10-1200; 21-1200; 31-1200; and 41-1200 fm/mg
c.p. (groups 3b-8b).
In EGFR-negative patients with lower PR concen-
trations the mean DFS values remained between 47 and
48 months, while in patients with relatively higher PR
concentrations they varied between 48 and 54 months.
The differences in the length of survival were 1-6 months
and were statistically non-significant (for example
Figure 5a).
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Figure 4c
Figures 4a, 4b, 4c. The DFS and OS curves of women with ER or PR
negligible values and EGFR-negative vel EGFR positive breast cancer.
In all cases the differences are statistically significant. The higher
EGFR levels and low ER or PR levels in breast cancer is associated
with poorer prognostic of women patients
Figure 4b
Figure 4a
Figure 5a. The DFS curves of women with EGFR-negative breast
cancer and relatively higher vel lower PR concentrations. The
differences are statistically non-significant
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Table IV. The relationships between DFS and OS of patients with breast cancer and the concentrations of PR in their EGFR-positive or EGFR-
negative tumours
N0 EGFR* Ranges of compared DFS – months OS – months
of PR concentrations Mean survival ± SE Significance  Mean ± SE Significance
group (fm/mg c.p.) (Confidence limit)# level** (Confidence limit)# level** 
(Number of cases ) Difference between Difference between
groups groups
– 0 – 4 (29) 47 ± 5 (38–56) 0.0315
1 vs 16 0.0596 – –
+ 0 – 4 (22) 31 ±  4 (23–40) 0.0448
– 0 – 9 (44) 47 ± 4 (40–54) 0.1372
2 vs 9 0.1763 – –
+ 0 – 9 (28) 38 ± 4 (30–47) 0.1519 
a) 0 – 4 (29) 52 ± 4 (44–59) 0.1065
– vs 6 0.1571
b) 5 – 1200 (90) 58 ± 2 (55–61) 0.1336
3 – –
a) 0 – 4 (22) 45 ± 5 (36–54) 0.0033
+ vs 23 0.0021
b) 5 – 1200 (47) 68 ± 2 (63–72) 0.0026
a) 0 – 9 (44) 47 ± 4 (40–54) 0.2317 54 ± 3 (49–60) 0.3277
– vs 6 0.2179 4 0.4402
b) 10 – 1200 (75) 53 ± 2 (48–58) 0.2259 58  ± 2 (54–61) 0.3882
4
a) 0 – 9 (28) 38 ± 4 (30–47) 0.0453 48 ± 4 (41–55) 0.0172
+ vs 15 0.0502 19 0.0123
b) 10 – 1200 (41) 53 ± 3 (53–67) 0.0472 67 ± 2 (63–72) 0.0144
a) 0 – 20 (59) 55 ± 3 (50–60) 0.4766
– vs 2 0.4209
b) 21 – 1200 (29) 57 ± 2 (53–61) 0.4433
5 – –
a) 0 – 20 (38) 49 ± 3 (43–55) 0.0040
+ vs 21 0.0034
b) 21 – 1200 (21) 70 ± 2 (65–75) 0.0035
a) 0 – 20 (59) 47 ± 3 (41–53) 0.9235
– vs 1 0.7905
b) 21 – 90 (29) 48 ± 4 (41–56) 0.8679
6 – –
a) 0 – 20 (38) 40 ± 4 (33–48) 0.0330
+ vs 16 0.0293
b) 21 – 90 (21) 56 ± 4 (48–63) 0.0308
a) 0 – 30 (68) 48 ± 3 (43–54) 0.3345 56 ± 2 (51–60) 0.8933
– vs 5 0.1975 1 0.7120
b) 31 – 1200 (51) 53 ± 3 (48–58) 0.2604 57 ± 2 (52–61) 0.7868
7
a) 0 – 30 (42) 42 ± 4 (35–50) 0.0329 52 ± 3 (46–58) 0.0210
+ vs 14 0.0220 18 0.0167
b) 31 – 1200 (27) 56 ± 3 (50–62) 0.0266 70 ± 3 (64–75) 0.0181
a) 0 – 40 (73) 48 ± 3 (43–54) 0.2890 56 ± 2 (51–60) 0.6316
– vs 6 0.1859 1 0.5159
b) 41 – 1200 (46) 54 ± 3 (48–59) 0.2336 57 ± 2 (53–62) 0.5549
8
a) 0 – 40 (48) 43 ± 3 (36–49) 0.0123 52 ± 3 (46–57) 0.0016
+ vs 16 0.0091 22 0.0022
b) 41 – 1200 (21) 59 ± 3 (54–64) 0.0104 74 ± 0 (74–74) 0.0018
# Confidence limits set at 95%
*EGFR- 0 – 9 fm/mg m.p.;*EGFR+ ≥10 fmol/mg m.p.
** Parameters of DFS and OS calculated by the Kaplan – Meier method; significance level between groups “a” and “b” calculated by
the Log rank test, the Breslow test and the Tarone – Ware test, results expressed as three consecutive values
In EGFR-positive patients with lower PR concen-
trations the mean DFS values remained between 38 and
43 months, while in patients with relatively higher PR
concentrations they varied between 53 and 59 months.
The differences in the length of survival were 14-16
months and were statistically significant (for example
Figure 5b).
In order to assess the impact of PR and EGFR
concentrations on OS of women with breast cancer we
used a similar approach as during DFS analysis. In
EGFR-negative patients presenting with lower PR
concentrations OS was 52-56 months, while in those with
higher PR concentrations – 57-58 months. The differences
between the groups varied between 1-6 months and were
statistically non-significant (for example Figure 6a).
In EGFR-positive patients presenting lower PR
concentrations OS was between 45 and 52 months, while
in those with higher PR concentrations – 67-74 months.
The differences between the groups varied between 18
and 23 months and were highly significant statistically
(e.g. Figure 6b).
Discussion
In the course of conducted studies we have shown that
there exists a statistically significant relation between the
concentration of ER in breast cancer tissue and DFS of
women patients. In patients with higher ER concentration
DFS is longer than in patients with lower ER concen-
trations. However, this relation becomes obvious only at
ER concentration of 30 fm/mg c.p. and is maintained at
all higher ER concentration. On the other hand ER
concentrations have no impact in OS of the same group of
patients. (Table I and Figure 1a and 1b).
The reports of other authors regarding this subject
tend to vary. Tsutsui et al. [19] have shown that ER
negative breast cancer patients have poorer survival
parameters (DFS – RR – 1.92 and OS – RR – 2.23) than
ER positive breast cancer patients. On the contrary,
Nicholson et al. [20] have proven, in the course of
a unilateral analysis, that ER is a significant prognostic
factor of DFS and OS, while in multivariate analysis the
influence of ER is non-significant.
In our other study we have applied Cox’s multi-
variate analysis to the same data and we have concluded
that ER presence is a positive prognostic factor of DFS,
but not of OS [9] However, the prognostic value of ER
for DFS depends on its concentration within the tumour.
When compared to reference concentrations of ER
(0-9 fm/mg c.p.), higher ER concentrations (91-400 fm/mg
c.p.), have a positive impact but lower ER (10-90 fm/mg
c.p.) – a negative impact on DFS of patients. The relative
risks (RR) were 0.28 and 2.25, respectively [9].
The present study has also shown that patients with
a higher PR concentration in their tumours achieve longer
DFS and OS. Contrary to the situation observed with ER
in case of PR concentration, the value from which
differences in survival were observed was very low or on
the verge of discernibility. It may be assumed that even
minimal PR concentrations increase the chance of longer
DFS and OS (Table II, Figure 2a and 2b).
Literature reports regarding the value of PR in the
prognosis of breast cancer are also contradictory. Results
resembling ours have been reported by Torregrosa et al.
[7]. In the course of a unilateral analysis they had
concluded that the PR status is a factor prognostic for
DFS and OS in breast cancer women patients, while in
a multivariate analysis they do not mention the impact of
PR status on patient survival. Castagnetta et al. [21] also
report PR status to have significant prognostic value in
breast cancer women patients. PR negative patients
present with earlier recurrences than PR positive patients.
Contradictory to our results, Ferrero et al. [11] report
that PR status has no impact on the survival of breast
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Figure 5b. The DFS curves of women with EGFR positive breast
cancer and relatively higher vel lower PR concentrations. The
differences are statistically significant
Figure 6a. The OS curves of women with EGFR negative breast cancer
and relatively higher vel lower PR concentrations. The differences are
statistically non-significant
Figure 6b. The OS curves of women with EGFR positive breast cancer
and relatively higher vel lower PR concentrations. The differences are
statistically significant
cancer women patients. Our other studies, in which
Cox’s multivariate analysis has been applied, have brought
us to similar conclusions – i.e. that PR concentration in
breast cancer tissue of women patients is an independent
prognostic factor of both DFS and OS. Higher PR
concentrations in the tumour tissue significantly decrease
the risk of recurrence and death [9, 10].
Contrary to PR status and, to a certain extent, to
ER status the present study has given us no evidence
of any statistically significant relations between the
concentration of EGFR in breast cancer tissue and
DFS and OS (Figure 3a and 3b). This is in direct
opposition to all our other observations, namely that
there exists a statistically significant negative correlation
between the concentrations of EGFR and ER or PR [2-4,
15]. In order to elucidate this issue we performed
a number of additional tests – we analysed how the
different ER and PR concentrations affect DFS and
OS of (i) EGFR-negative patients (i.e. EGFR concen-
tration of 0-9 fm/mg m.p.) and (ii) EGFR-positive patients
(i.e. concentrations of 10-100 fm/mg m.p.).
In the course of these tests we have concluded that
EGFR concentration may differ in its impact on DFS
and OS, depending on the lack of or presence of ER or
PR in the cancer tissue. In EGFR-positive patients, in
whom ER or PR concentrations in cancer tissue were
negligible, DFS and OS were shorter by 10-22 months, as
compared to EGFR-negative patients with higher ER or
PR concentrations (see Table III, group 1-3 and Table
IV group 1). In women patients in whom cancer tissue
shows a lack of ER or PR, or their very low concen-
trations, the presence of EGFR negatively affects DFS
and OS (Figures 4a, 4b and 4c).
In EGFR-positive patients with positive ER and PR
status DFS and OS were longer by 11-23 months than in
EGFR-positive patients with lower ER or PR concen-
trations (Table III, groups 7-8 DFS and Table IV group
3-7 DFS and OS). It is therefore clear that there exists
a synergistic effect in the impact of positive ER, PR and
EGFR status on DFS and OS. We have not found such
a communication in literature as to date.
In the aforementioned study based on Cox’s
multivariate analysis we have confirmed this observation
[9]. It is obvious that, taken separately, EGFR status does
not influence neither DFS nor OS, but in the presence of
positive ER and PR status it becomes a positive
prognostic factor; while when accompanied by the lack
of ER and PR it is a significantly negative prognostic
factor [9].
EGFR as a prognostic factor for breast cancer
patient survival first appeared in a paper by Sainsbury et
al. [8], where it was pronounced to be a negative
prognostic factor for the survival of women with breast
cancer. Since then many papers were published regarding
this issue [7, 19]. Nicholson et al. [20] report in the course
of both single-arm and multivariate analysis that EGFR is
a significant prognostic of DFS and OS. Tsutsui et al. [22]
report it to be an independent and significant prognostic
factor, but only if the ER status of the tumour is omitted
in the course of a multivariate analysis. On the other
hand, if ER is not omitted, EGFR loses its independence
due to the lack of statistical significance. Torregrosa et
al. [7] have shown that in Cox’s multivariate analysis
EGFR is an independent significant prognostic factor
only for OS, while for DFS it is non-significant – in both
these analyses the ER status was included. It is quite
likely that these discrepancies arise from the possibility of
difference of the studied material, from varied methods
applied for the assessment of EGFR expression (radio-
ligands or immunohistochemical staining) and from
different statistical approaches (Kaplan-Meier, various
forms of Cox’s multivariate analysis). Besides one must
consider the fact that a majority of authors refer to
receptor status as positive (+) or negative (-) [8, 23]. This
may introduce disarray into the assessment analyses,
especially in the case of positive receptor status. The
assessment of the expression of EGFR by immuno-
histochemical staining may be charged with subjective
errors. Our studies were performed as quantitative assays,
therefore the concentrations of ER, PR and EGFR were
presented as defined numeric values. Concentration of
EGFR in few analyses was also expressed as
EGFR-negative (0-9 fm/mg m.p.) or EGFR-positive (≥10
– 100 fm/mg m.p.) ranges, but in these cases negativity or
positivity are presented as a defined range of values of the
receptor concentration.
To summarise, it may be stated from our results that
EGFR is a very important prognostic factor indicating
the course of disease in cases of breast cancer, but its
impact depends upon the ER and PR status of the breast
cancer tissue.
Conclusions
1. There exists an evident relationship between the length
of postoperative disease free survival (DFS) of women
with breast cancer and both ER and PR concentration
within the tissues of the primary tumour. Women with
greater ER or PR concentrations present with longer
DFS and women with lower PR concentrations – with
shorter DFS.
2. There exists a statistically significant positive relation
between overall survival (OS) of women with primary
breast cancer and the PR concentration in their cancer
tissue. However, there exists no such relation of OS
with ER concentration.
3. There is no relation between EGFR concentration in
breast cancer tissue and both postoperative
disease-free survival (DFS) and overall survival (OS) of
patients. However, such a relation may be observed
when EGFR concentration is analysed in view of ER
and PR concentrations within the cancer tissue.
A detailed analysis of this phenomenon has allowed us
to conclude as follows:
a. The presence of higher concentrations of EGFR
in breast cancer tissue with a concomitant lack of
ER relates to shorter DFS and OS of patients; while
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the concomitant lack of both EGFR and ER relates to
longer DFS and OS.
b. Patients presenting with higher concentrations of
EGFR and ER or EGFR and PR in their breast
cancer tissue achieve longer DFS and OS, as
compared to women presenting with high EGFR
concentrations and negligible concentrations of ER
or PR.
To summarise – we believe that the influence of
EGFR status in breast cancer tissue on the survival of
women patients depends upon the ER and PR status of
the tumour. In the presence of high concentrations of
ER or PR in breast cancer tissue high concentration of
EGFR have a positive impact on DFS and OS of patients,
while with the concomitant lack of PR and ER high
EGFR concentrations affect both DFS and OS of patients
negatively.
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